Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND FAMOTIDINE versus TENATHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND FAMOTIDINE versus TENATHAN.
IBUPROFEN AND FAMOTIDINE vs TENATHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever. Famotidine is a histamine H2-receptor antagonist that inhibits gastric acid secretion by blocking histamine at H2 receptors on gastric parietal cells.
TENATHAN is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, leading to increased serotonin levels in the synaptic cleft.
One tablet (ibuprofen 800 mg/famotidine 26.6 mg) orally three times daily.
1 tablet (40 mg) orally once daily, increased to 80 mg once daily if needed after 4 weeks.
None Documented
None Documented
Ibuprofen: Terminal half-life 2-4 hours (normal renal function); prolonged to 3-6 hours in elderly or hepatic impairment. Famotidine: Terminal half-life 2.5-3.5 hours (normal renal function); extended to >20 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is 4-6 hours; in severe renal impairment (CrCl <30 mL/min) may extend to 8-12 hours, requiring dose adjustment.
Ibuprofen: Renal excretion of metabolites (90%) and unchanged drug (<10%); biliary/fecal (minor). Famotidine: Renal excretion of unchanged drug (65-70%); metabolites (25-30%); biliary/fecal (minor).
Primarily renal excretion as unchanged drug (60-70%) and metabolites (20-30%); biliary/fecal elimination accounts for <10%.
Category D/X
Category C
NSAID
NSAID